Petros Pharmaceuticals (NASDAQ:PTPI) Trading Down 2.1%

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI)’s stock price dropped 2.1% during trading on Wednesday . The company traded as low as $0.64 and last traded at $0.69. Approximately 457,077 shares were traded during trading, a decline of 55% from the average daily volume of 1,006,999 shares. The stock had previously closed at $0.71.

Petros Pharmaceuticals Price Performance

The stock’s fifty day moving average is $1.36 and its 200 day moving average is $1.37. The company has a current ratio of 1.89, a quick ratio of 1.74 and a debt-to-equity ratio of 0.57.

Petros Pharmaceuticals (NASDAQ:PTPI) last issued its quarterly earnings data on Monday, April 1st. The company reported ($2.17) earnings per share (EPS) for the quarter. The company had revenue of ($0.36) million for the quarter. Petros Pharmaceuticals had a negative net margin of 181.87% and a negative return on equity of 68.90%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in PTPI. BlackRock Inc. increased its position in Petros Pharmaceuticals by 880.2% during the 1st quarter. BlackRock Inc. now owns 191,715 shares of the company’s stock valued at $300,000 after purchasing an additional 172,156 shares during the period. Virtu Financial LLC purchased a new position in Petros Pharmaceuticals during the 2nd quarter valued at $44,000. Vanguard Group Inc. increased its position in Petros Pharmaceuticals by 114.8% during the 3rd quarter. Vanguard Group Inc. now owns 255,914 shares of the company’s stock valued at $131,000 after purchasing an additional 136,773 shares during the period. Renaissance Technologies LLC purchased a new position in Petros Pharmaceuticals during the 2nd quarter valued at $34,000. Finally, Schonfeld Strategic Advisors LLC purchased a new position in Petros Pharmaceuticals during the 2nd quarter valued at $47,000. 12.34% of the stock is owned by hedge funds and other institutional investors.

Petros Pharmaceuticals Company Profile

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).